Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

Nature Medicine
Mario DelgadoR P Gomariz

Abstract

Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease of unknown etiology, characterized by chronic inflammation in the joints and subsequent destruction of the cartilage and bone. We describe here a new strategy for the treatment of arthritis: administration of the neuropeptide vasoactive intestinal peptide (VIP). Treatment with VIP significantly reduced incidence and severity of arthritis in an experimental model, completely abrogating joint swelling and destruction of cartilage and bone. The therapeutic effect of VIP was associated with downregulation of both inflammatory and autoimmune components of the disease. Our data indicate VIP as a viable candidate for the development of treatments for RA.

References

Mar 1, 1996·Arthritis and Rheumatism·M WalmsleyM Feldmann
Jan 1, 1996·Annual Review of Immunology·M FeldmannR N Maini
Jan 1, 1997·Life Sciences·L K MyersA H Kang
Jan 1, 1997·Peptides·P GourletP Robberecht
Jun 25, 1999·Pharmacy World & Science : PWS·H J Dinant, B A Dijkmans
Jan 19, 2000·Immunology Today·D PozoJ R Calvo

❮ Previous
Next ❯

Citations

Jan 31, 2002·Arthritis and Rheumatism·Richard O Williams
Jan 4, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Satomi OnoueShizuo Yamada
Apr 3, 2010·Cancer Immunology, Immunotherapy : CII·Tobias BoppHansjörg Schild
Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Doina GaneaMario Delgado
Dec 4, 2013·Expert Reviews in Molecular Medicine·Anne M Pesenacker, Lucy R Wedderburn
Dec 6, 2012·Molecular Pharmaceutics·Varun SethiHayat Onyuksel
Mar 30, 2011·Immunology and Cell Biology·Rebeca JimenoYasmina Juarranz
Jan 14, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Miguel G ToscanoDoina Ganea
Dec 23, 2006·Nature Reviews. Immunology·Elena Gonzalez-ReyMario Delgado
Oct 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Catalina AbadJames A Waschek
May 16, 2007·The Journal of Experimental Medicine·Tobias BoppEdgar Schmitt
Feb 3, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Neil FosterPaul A Barrow
Jul 1, 2010·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Sarah GerloRon Kooijman
May 14, 2010·Rheumatology·Ellen J WehrensBerent J Prakken
Apr 23, 2003·Current Opinion in Rheumatology·Joseph C ShanahanRobert H Carter
Dec 8, 2006·Annals of the Rheumatic Diseases·Elena Gonzalez-ReyMario Delgado
Nov 21, 2007·Annals of the Rheumatic Diseases·Elena Gonzalez-ReyMario Delgado
Aug 8, 2009·American Journal of Physiology. Gastrointestinal and Liver Physiology·Xuan-Zheng Shi, Sushil K Sarna
Dec 13, 2007·Neuroimmunomodulation·Javier LecetaYasmina Juarranz
Jul 8, 2011·Neuroendocrinology·Luciana Souza-MoreiraElena Gonzalez-Rey
May 6, 2010·American Journal of Respiratory and Critical Care Medicine·Antje PrasseJoachim Müller-Quernheim
Apr 7, 2004·The Journal of Clinical Investigation·Marlon P QuinonesSeema S Ahuja
May 9, 2013·Journal of Translational Medicine·Angela StorkaMichael Wolzt
Dec 19, 2003·Arthritis Research & Therapy·Farideh EskandariEsther M Sternberg
Jan 11, 2014·PloS One·Carmen MartínezIsidoro González-Álvaro
Jul 19, 2011·World Journal of Biological Chemistry·Glenn Paul DorsamSandeep Batra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.